Our people
It takes a special commitment to keep pushing the boundaries. To keep believing. To never give up.
"I am really excited to be able to play a significant role in the new Alliance Laboratory with Cancer Research UK. Collaborating with CRUK and accessing oncology knowledge from the scientists within those thousands of groups is going to help us to find some really novel targets so we can generate innovative therapeutics to help cancer patients."
Leading scientific expertise
We combine a unique range of knowledge, skills and experience with a passion for following the science. Here are some examples of our key capabilities.
Partnering: a way of life
We work alongside scientists at leading institutions to better understand disease, identify potential new drugs and accelerate drug development. We’re also pioneers in creating a more open research environment.
Giving UK academia access to AstraZeneca compounds
In 2011, our landmark agreement with the UK Medical Research Council gave UK academic researchers unprecedented access to 22 of our compounds. Watch our video to hear about the progress these scientists are making.
Clinical trial collaboration explores novel immuno-oncology combinations
"Our partnership with AstraZeneca allows us to explore new and potentially transformational treatment combinations on haemotological and solid tumours. Both parties bring deep scientific expertise, and by sharing this we're expanding treatment options for patients."
Where science thrives
Our research sites are collaborative, innovative and dynamic environments that allow our scientists to keep pushing the boundaries
Cambridge
Cambridge, United Kingdom
Our new facility in Cambridge will bring together our small molecule and biologics research and development activity. It will become our largest centre for oncology research and also house scientists focused on cardiovascular and metabolic diseases, respiratory, inflammation and autoimmune diseases and conditions of the central nervous system.
Gothenburg
Gothenburg, Sweden
Our vibrant science facility in Gothenburg is a world-leading centre for research and development in cardiovascular and metabolic diseases, and respiratory, inflammation and autoimmunity. It also houses science teams responsible for all phases and aspects of small molecule drug discovery and development – from initial ideas through to new medicines.
Gaithersburg
Gaithersburg, Maryland, USA
Our Gaithersburg centre is headquarters to MedImmune and our primary location for biologics research and development in the US. It is also home to our Global Medicines Development function and Specialty Products Group. The modern, vibrant, scientific campus employs more than 3,000 experts in our field and is only a short drive from Washington, DC.
Two R&D organisations with one shared goal
Our two R&D organisations (BioPharmaceuticals and Oncology) are responsible for discovery through to late-stage development. This structure is designed to enable us to follow the science by accelerating promising early-stage assets and life-cycle management programmes, as well as providing new opportunities for combinations.
An exciting pipeline
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
164
projects in our pipeline
9
new molecular entities in our late-stage pipeline
1
new molecular entity approval in the last quarter
Join AstraZeneca
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.